

## Overview of Intracoronary Brachytherapy for the In-stent Restenosis of a Drug-eluting Stent

Soheila Refahi<sup>1</sup>, Mohsen Mohammadi<sup>2\*</sup>

<sup>1</sup> Medical Physics Specialist, Department of Medical Physics, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran

<sup>2</sup> Msc of Radiobiology and Radiation Protection, Department of Medical Radiation Science, School of Paramedicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

### ARTICLE INFO

Article type:  
Review Article

Article history:  
Received: 29 Jan 2019  
Revised: 21 Feb 2019  
Accepted: 25 Feb 2019

Keywords:  
Coronary Intervention  
Drug-Eluting Stent  
In-Stent Restenosis  
Intracoronary Brach Therapy  
Percutaneous

### ABSTRACT

Percutaneous coronary intervention with stenting is considered recently as the most common procedure for the treatment of symptomatic coronary. The article reviewed 41 studies published during 1997-2019 on intracoronary brachytherapy for in-stent restenosis of a drug-eluting stent. Intracoronary radiation therapy was finally confirmed in the setting of in-stent restenosis using as adjunctive therapy. Irradiation dose to vessels may result in fibrosis, which can, in turn, cause the late formation of an aneurysm due to the weakness of the vessel wall. Intracoronary brachytherapy is a critical treatment which should not be ignored.

► Please cite this paper as:

Refahi S, Mohammadi M. Overview of Intracoronary Brachytherapy for the In-stent Restenosis of a Drug-eluting Stent. J Cardiothorac Med. 2019; 7(1): 400-405.

### Introduction

Percutaneous coronary intervention [PCI] with stenting is recently the most usable symptomatic coronary treatment procedure (1). However, these stents may lead to in-stent restenosis (ISR), which requires to repeat revascularization. This issue may increase the rate of mortality and pose a therapeutic challenge (2). The principal mechanism of ISR after the implantation of the stent is the proliferation of neointimal tissue due to the damaged arterial wall (3). Neointimal tissue proliferation might be focal or aligned with the length of the stent distributed uniformly. The ISR, which occurs early during the deployment of the stent, is through elastic recoil and relocation of axially transmitted plaque. The reasons for late (weeks to months) ISR are generally the reorganization of thrombus, neointima remodeling and formation (1).

The negative effect of endothelin-1 on blood

vessels may be associated not only with its vasoconstrictor properties but also with its mitogenic effects. There have been a few reports of an increase in the concentration of endothelin-1 after angioplasty, which results from mechanical damage to the vascular wall although it does not appear to be significant in all papers (4).

Neointimal proliferation is still another factor contributing to ISR. The stimulation of neointima formation occurs due to the injured vessel in the PCI and deployment of the stent. Plenty of these incidents are due to the medial and intimal damage, leading to the proliferation and migration of vascular smooth cells in muscle, the formation of extracellular matrix, which finally activates the coagulation-fibrinolysis system (1, 5, 6). The occurrence of neoatherosclerosis was considerably greater in

\*Corresponding author: Mohsen Mohammadi, Department of Medical Radiation Sciences, School of Paramedicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: 04531422266; Email: Mradiobiology313@gmail.com

© 2019 mums.ac.ir All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

drug-eluting stent (DES) compared to BMS (31% vs 16%,  $P < 0.001$ ) (1).

The independent risk factors for neoatherosclerosis include younger age, longer use of an implant, sirolimus-eluting stent usage, paclitaxel-eluting stent utilization, and underlying unstable plaques (1, 7). Restenosis immediately after percutaneous coronary revascularization is defined as a decrease of 50% or higher in the luminal diameter after angiography. However, on the basis of the literature, the prevalence of restenosis after only balloon angioplasty was 40-50%. Bare metal stents (BMS) eliminates restenosis to almost 20% (8, 9). In the first months of the 2000s, DES plus extenuated were introduced as the target lesion revascularization, which decreased up to 50% or more, compared to BMS (9, 10). The DESs demonstrated the considerable reduction of restenosis and the necessity for recurrent intervention, which was in contrast with bare metal stents in pivotal trials (11, 12). Despite these, the frequency of ISR in DES is up to 20%. Some patients failing DES have confined options of salvage and mostly numerous medical comorbidities, originally increase their risk (8, 9).

It was assumed that intracoronary irradiation can decrease neointimal proliferation and vascular smooth muscle proliferation after the procedure of the balloon overstretch, that can barricade or decrease ISR. Some studies illustrated a considerable decrease in the rating area of restenosis mid endovascular radiation in animal models (9). Treatment with intracoronary radiation was eventually confirmed in the setting of ISR in BMS as adjunctive therapy, using several trials indicating the improved percent of angiographic restenosis, major cardiac incidents, and aimed lesion revascularization (9, 10). Although the best treatment for the recurrent ISR of DES (i.e., restenosis that follows second DES or drug-eluting balloon), this setting in which case brachytherapy can be particularly more beneficial, compared to bare metal stent (13). The foundation for brachytherapy is a conceptualization of the fact that one part of restenosis is neointimal hyperplasia, a natural replication to the tissue injury made by balloon expansion in an arterial segment (8). Cellular proliferation fills in voids in the media and may develop into the arterial lumen. The intracoronary concept brachytherapy is that locally used radiation may eliminate or attenuate neoproliferation (13-15).

The Beta-Cath System [Novoste, Inc., Norcross, GA] and the CHECKMATE System [Cordis Corp., Miami, FL], confirmed by the Drug and Food Administration in November 2000 for daily usage (16-19), are first two commercial systems for

coronary irradiation. The system which is called Novoste is a manually acted hydraulic system that applies a non-centered radioactive particle fount train [2.3-mm diameter] of  $^{90}\text{Sr}$  pellets, which give out high-energy  $\beta$ -particles [ $b_{\text{max}}$  2.28 MeV] by the decay of the  $^{90}\text{Y}$  daughter (16, 20). In return, the Cordis system is composed of a high-activity [7.4–18.5 GBq]  $^{192}\text{Ir}$  wire source that is developed by an automated loader machine (16, 19, 21). Any system which uses a high-dose percent, by a 3-6-min vessel dwell time [i.e., required time to place the radioactive resource in the vessel target area to radiation delivery] for a resource of the Novoste and a 15-20-min dwell time is required for the Cordis machine (16, 17, 47). The whole dose requirements for the Beta-Cath System, as an example, are 23.0 Gy and 18.4 Gy in large and small vessels, respectively, which measures at 2 mm radially from the center of the source, and 8–30 Gy at 2 mm distance from the center of the source for the CHECKMATE system (16, 19, 22). The multiple trials, apply either gamma or beta radiation sources, show the brachytherapy's effectiveness in the decreased occurrence of ISR. The brachytherapy was developed to the era of BMS due to its ease of use and effectiveness resulted in the replacement of DES with the ordinary brachytherapy (15). This study aimed to provide an overview of intracoronary brachytherapy for the ISR of DES.

## Materials and Methods

This systematic review of papers addressed the evaluation of the intracoronary brachytherapy for the ISR of DES. In doing so, four databases, including Medline, PubMed, Science Direct, and Google Scholar, were searched for the relevant clinical and experimental studies published during 1997-2019.

The search focused on randomized, clinical, and experimental studies published in English. The literature search was performed using a combination of medical subject headings (MeSH) ("Intracoronary Brachytherapy" or "Drug-Eluting Stent [DES]" or "In-Stent Restenosis [ISR]" or "Percutaneous Coronary Intervention [PCI]").

## Results

Various studies have been conducted on this issue in recent years (Table 1). In one of these studies, the researchers examined more than 250 patients who were treated by ICBT after percutaneous transluminal coronary angioplasty. As can be seen in table 1, the obtained results indicated that vascular brachytherapy integration in the catheterization laboratory was both secure and practical (8, 32, 11, 46).

**Table 1.** Results of clinical studies of adjuvant intravascular brachytherapy

Study group	Year	Article title	Conclusions
Mithun J	2019	Intravascular Brachytherapy for the Management of Repeated Multimetal-Layered Drug-Eluting Coronary Stent Restenosis	Intravascular brachytherapy led to significantly lower major adverse cardiac events in patients with multilayered drug-eluting stents restenosis.
J.M. DeCunha	2018	A new delivery system to resolve dosimetric issues in intravascular brachytherapy	We hope that our proposed delivery system and other developments allow for the introduction of a second generation of intravascular brachytherapy delivery systems that will improve patient outcomes and patient safety and present a viable solution to the problem of DES-ISR.
Ron Waksman,	2017	Diagnosis and management challenges of in-stent restenosis in coronary arteries	Drug-eluting balloons should be used as first line therapy for bifurcation restenosis to prevent excess metal at the carina.
Ron Waksman,	2016	In-Stent Restenosis? The Raiders of the Magic Remedy	The interventional cardiologists will be able to declare success in finding the remedy for DES-ISR by elimination of the stent and its late complications.
Nisha Ohri MD	2016	Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents	Intracoronary brachytherapy is a safe and well-tolerated treatment option that may serve as a form of salvage therapy for high-risk patients with recurrent ISR of DES.

## Discussion

Ionizing radiation has efficiently been used as adjunctive therapy if necessary (23-26) for de novo coronary stenosis and ISR in controlled studies. In the early 1990s, endoluminal radiation in atherosclerotic lesions was considered for animal models (27, 28). The implication of restenosis of DES has grown in recent years due to its expanded usage for complex coronary lesions in high-risk patients. The rate of DES-ISR has been reported as 3-20%, which is closely related to DES type, the follow-up date, and the lesions convolution (1, 29). The DES is dependent on lower ISR, compared to BMS (1, 30).

However, DES has noticeably decreased the rate of ISR compared to BMS. There is a considerable number of patients with high risks of cardiac problems, who have developed ISR of DES and they have gained the desirable results from standard treatments (8, 9). Furthermore, since patients have different stents levels in the lesion, extra procedures carry incremented risk. To explain this clinical event, the high volume cardiac catheterization laboratory plays the key role in the intracoronary brachytherapy (ICBT) of patients who have recurrent ISR of DES (8).

The utilization of ionizing radiation for the decrease of restenosis due to myointimal hyperplasia after the endovascular intervention is a promising innovative tool (31, 32). The safety of intracoronary brachytherapy procedure has already been documented by a German group in 2000 (8, 33).

Besides the Novoste Beta-Cath system, ICBT implied non-stent restenosis and ISR for treatment of de novo lesions. A total number of 92 patients with 104 lesions were treated through this method using the dose range of 14-20 Gy. There were no reports of acute complications, including deaths, related to the

procedure, stent thrombosis, or infarcts. The other Dutch group published the outcomes of ICBT in 2000 (8, 34).

However, brachytherapy is technically a simple method, which poses numerous difficulties, such as dosimetry exposures of cardiac catheterization laboratory staff and patient as well as time limitations (35). Exposure to radioactive substances, particularly gamma radiation, needs numerous safety precautions. Furthermore, routine shielding is essential for the laboratories of cardiac catheterization. Radiation sources [Ir or Sr] have confined half-life, so renewal is important. Treatment procedure takes 20 min for gamma and 3-10 min for beta radiation, and it needs time to advance and remove the catheters (36, 37). If ICBT implies into routine practice, then its practicality and effectiveness have the same importance. At present ICBT generally needs to the transfer of the patient to a radiotherapy suite, which can add 30±45 min to the procedure; however, the real irradiation element needs only 200±656 s.

Vascular brachytherapy is accessed in some centers in the United States and is used initially for the DES-ISR recurrence; however logistic issues and absence of radiation oncology support hinder its utilization (1). Considering the obtained outcome of experimental dosimetric studies, the tissue reaction's morphology was documented on endoluminal radiation therapy (38, 39), such as the primary phase I and II brachytherapy trials. Moreover, these randomized trials revealed that the rate of subacute thrombosis and even thrombosis with delay could be higher, compared to the expected rate (37, 40). The term subacute thrombosis is applied for incidents happening during 1-6 months, but thrombosis with a delay is used for events of 6 months (37).

The other possible problem is related to the formation of an aneurysm at the treatment location. Irradiation dose to vessels may result in fibrosis, which can, in turn, cause the late formation of an aneurysm due to the weakness of the vessel wall (32, 40, 42). The obtained results revealed that although the regeneration of endothelial after brachytherapy decreased for 6-12 months, each reaction of an inflammatory was followed with neoendothelial hyperplasia in several cases. This means that restenosis was not prevented but delayed in time (37).

Another factor which can be related to the polymer is long-term inflammation or hypersensitivity reaction (41). According to the papers on brachytherapy using angiographic follow-up, it revealed that restenosis was more frequent at the stent edges. Numerous names have been utilized to explain this event, such as the effect of the candy wrapper, which is due to the mitotic stimulation of low-dose radiation in the segment's edges of the radiating catheter (37, 43). This event considerably reduces the benefits of brachytherapy and needs alternative treatment. In this regard, it has been proposed endothelial trauma is essential apart from the decreased dose of radiation at the edges of the stent. For inhibition, we must radiate the longer segments of the arterial wall, although this solution could not solve the problem completely (37).

There is no evidence for local problems, including local malignancy or damages of nerve after a relatively short follow-up period. However, numerous studies have only enrolled elderly patients due to the potential possibility of malignancy progress (44-46). However, our recent outcomes illustrated that ICBT is a secure and well-tolerated procedure in high-cardiac-risk patients. The more studies about the ICBT efficacy as a form of salvage therapy is warranted for recurrent the ISR of DES are accepted (8, 9).

## Conclusion

The DES's in-stent restenosis is a significant clinical issue. Intracoronary brachytherapy is a secure and well-tolerated treatment option, which can serve as a type of salvage therapy for high-risk patients with the recurrent ISR of DES. Intracoronary brachytherapy is a critical treatment, which should not be ignored.

## Acknowledgments

The authors would like to thank the hospital chief and Imaging Department of Imam Khomeini Hospital in Ardebil for their sincere cooperation.

## Conflict of Interest

Authors declared no conflicts of interests.

## References

- Alraies MC, Darmoch F, Tummala R, Waksman R. Diagnosis and management challenges of in-stent restenosis in coronary arteries. *World J Cardiol.* 2017; 9:640.
- Waksman R, Steinvil A. In-stent restenosis? The raiders of the magic remedy. *Am Heart Assoc.* 2016; 9:e004150.
- Piccolo R, Stefanini GG, Franzone A, Spitzer E, Blöchlinger S, Heg D, et al. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis. *Circulation.* 2015; 8:e002223.
- Derkacz A, Szymczyszyn A, Szahidewicz-Krupska E, Protasiewicz M. Effect of endovascular coronary low-level laser therapy during angioplasty on the release of endothelin-1 and nitric oxide. *Age.* 2017; 14:687.
- Minar E, Pokrajac B, Maca T, Ahmadi R, Fellner C, Mittlböck M, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. *Circulation.* 2000; 102:2694-9.
- Wolfram RM, Pokrajac B, Ahmadi R, Fellner C, Gyongyosi M, Haumer M, et al. Endovascular brachytherapy for prophylaxis against restenosis after long-segment femoropopliteal placement of stents: initial results. *Radiology.* 2001; 220:724-9.
- Neamtu I, Chiriac AP, Diaconu A, Nita LE, Balan V, Nistor MT. Current concepts on cardiovascular stent devices. *Mini Rev Med Chem.* 2014; 14:505-36.
- Ohri N, Sharma S, Kini A, Baber U, Aquino M, Roy S, et al. Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents. *Adv Radiat Oncol.* 2016; 1:4-9.
- Negi SI, Torguson R, Gai J, Kiramijyan S, Koifman E, Chan R, et al. Intracoronary brachytherapy for recurrent drug-eluting stent failure. *JACC.* 2016; 9:1259-65.
- Iofina E, Radke P, Schubert D, Langenberg R, Blindt R, Hanrath P, et al. Three-year follow-up after intracoronary beta-radiation therapy for in-stent restenosis. *Catheter Cardiovasc Interv.* 2006; 67:600-6.
- Kleiman NS. Too Thick to Cut With SISRs: Brachytherapy in Multilayer Drug-Eluting Stent Restenosis. (2019).
- Garg S, Smith K, Torguson R, Okabe T, Slottow TL, Steinberg DH, et al. Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. *Catheter Cardiovasc Interv.* 2007; 70:9-14.
- Roa DE, Song H, Yue N, d'Errico F, Nath R. Measured TG-60 dosimetric parameters of the Novoste Beta-Cath 90Sr/Y source trains for intravascular brachytherapy. *Cardiovasc Radiat Med.* 2002; 3:199-204.
- Moosavi-Movahedi AA, Golchin AR, Nazari KK, Chamani J, Saboury AA, Bathaie SZ, Tangestani-Nejad S. Microcalorimetry, energetics and binding studies of DNA-dimethyltin dichloride complexes. *Thermochim Acta.* 2004; 414: 233-241.
- Williams DO, Sobieszczyk P. Coronary brachytherapy 2016. *JACC Cardiovasc Interv.* 2016; 9:1266-8.



16. Knapp FF, Spencer RH, Kropp J. Intravascular radiation therapy with radioactive liquid-filled balloons for inhibition of restenosis after angioplasty: a new opportunity for nuclear medicine? *J Nucl Med.* 2001; 42:1384-7.
17. Weinberger J, Giedd KN, Simon AD, Marboe C, Knapp FF, Trichter F, et al. Radioactive beta-emitting solution-filled balloon treatment prevents porcine coronary restenosis. *Cardiovasc Radiat Med.* 1999; 1:252-6.
18. Chamani J, Heshmati M. Mechanism for stabilization of the molten globule state of papain by sodium n-alkyl sulfates: spectroscopic and calorimetric approaches. *J Colloid Interface Sci.* 2008; 322: 119-127.
19. Kiavar O, Sadeghi M. Modeling and dose calculations of a pure beta emitting sup 32P coated stent for intracoronary brachytherapy by Monte Carlo code. *Int J Radiat Res.* 2012; 9:257-63.
20. Monroy-Guzman F, Almaraz VB, Gutierrez TR, Cohen LG, Nava PR, Rosales CJ, et al. Development of inorganic adsorbents as matrices of generators for therapeutic radionuclides. Therapeutic radionuclide generators: 90 Sr/90 Y and 188 W/188 Re generators. Vienna: International Atomic Energy Agency; 2009.
21. Jaeckel B, Cripps R, Guntay S, Bruchertseifer H. Development of semi-automated system for preparation of 188Re aqueous solutions of high and reproducible activity concentrations. *Appl Radiat Isotopes.* 2005; 63:299-304.
22. Sarkar SK, Venkatesh M, Ramamoorthy N. Evaluation of two methods for concentrating perhenate (188Re) eluates obtained from 188W-188Re generator. *Appl Radiat Isotopes.* 2009; 67:234-9.
23. Mohammadi M, Islamian JP, Karami H, Oladghaffari M, Farajollahi A, Nejati-Koshki K. Role of HDM2 gene in radio-sensitivity of esophageal cancer cell lines to irradiation. *Int J Cancer Manag.* 2017; 10:6.
24. Islamian JP, Mohammadi M, Baradaran B, Farajollahi A, Aghamiri SM, Jafarabadi MA, et al. Enhancing radiosensitivity of TE1, TE8, and TE 11 esophageal squamous carcinoma cell lines by Hdm2-siRNA targeted gene therapy in vitro. *Bioimpacts.* 2016; 6:93-8.
25. Islamian JP, Mohammadi M, Baradaran B. Inhibition of human esophageal squamous cell carcinomas by targeted silencing of tumor enhancer genes: an overview. *Cancer Biol Med.* 2014; 11:78.
26. Rahgoshai S, Mohammadi M, Refahi S, Oladghaffari M, Aghamiri SM. Protective effects of IMOD and cimetidine against radiation-induced cellular damage. *J Biomed Phys Eng.* 2018; 8:133.
27. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. *N Engl J Med.* 2001; 344:250-6.
28. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. *Circulation.* 2003; 108:1701-6.
29. Hedman M, Hartikainen J, Syväne M, Stjernvall J, Hedman A, Kivelä A, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). *Circulation.* 2003; 107:2677-83.
30. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation.* 2007; 115:2344-51.
31. Zolfagharzadeh M, Pirouzi M, Asoodeh A, Saberi MR, Chamani J. A comparison investigation of DNP-binding effects to HSA and HTF by spectroscopic and molecular modeling techniques. *J Biomol Struct Dyn.* 2014; 32:1936-1952.
32. Hansrani M, Overbeck K, Smout J, Stansby G. Intravascular brachytherapy: a systematic review of its role in reducing restenosis after endovascular treatment in peripheral arterial disease. *Eur J Vascular Endovasc Surg.* 2002; 24:377-82.
33. Kotzerke J, Hanke H, Höher M. Endovascular brachytherapy for the prevention of restenosis after angioplasty. *Eur J Nucl Med.* 2000; 27:223-36.
34. Sabaté M, Costa MA, Kozuma K, Kay IP, Van Der Wiel CJ, Verin V, et al. Methodological and clinical implications of the relocation of the minimal luminal diameter after intracoronary radiation therapy. *J Am Coll Cardiol.* 2000; 36:1536-41.
35. Mohammadi M, Danaee L, Alizadeh E. Reduction of radiation risk to interventional cardiologists and patients during angiography and coronary angioplasty. *J Tehran Univ Heart Center.* 2017; 12:101.
36. Sanei H, Asoodeh A, Hamedakbari-Tusi S, Chamani J. Multi-spectroscopic investigations of aspirin and colchicine interactions with human hemoglobin: binary and ternary systems. *J Solution Chem.* 2011; 40:1905-1931.
37. Pavlides GS. Brachytherapy for treatment of restenosis after percutaneous coronary intervention. *Hellenic J Cardiol.* 2002; 43:216-8.
38. Schroeder S, Kopp AF, Baumbach A, Meisner C, Kuettnner A, Georg C, et al. Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. *J Am Coll Cardiol.* 2001; 37:1430-5.
39. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. *N Engl J Med.* 1997; 336:1697-703.
40. Sheppard R, Eisenberg MJ. Intracoronary radiotherapy for restenosis. *Mass Medical Soc.* 2001; 344:295-7.
41. Torguson R, Sabate M, Deible R, Smith K, Chu WW, Kent KM, et al. Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. *Am J Cardiol.* 2006; 98:1340-4.
42. Waksman R, Bhargava B, Leon MB. Late thrombosis following intracoronary brachytherapy. *Catheterizat Cardiovasc Interv.* 2000; 49:344-7.
43. Tangwongsan C, Chachati L, Webster JG, Farrell PV. In vitro calibration of a system for measurement of in vivo convective heat transfer coefficient in animals. *Biomed Eng Online.* 2006; 5:57.

44. Naeeminejad S, Assaran Darban R, Beigoli S, Saberi MR, Chamani J. Studying the interaction between three synthesized heterocyclic sulfonamide compounds with hemoglobin by spectroscopy and molecular modeling techniques. *J Biomol Struct Dyn*. 2017; 35: 3250-3267.
45. Regar E, Kozuma K, Sianos G, Coen VL, van der Giessen WJ, Foley D, et al. Routine intracoronary beta-irradiation. Acute and one year outcome in patients at high risk for recurrence of stenosis. *Eur Heart J*. 2002; 23:1038-44.
46. De Benedetti E, Latchem D, Roguelov C, Coucke P, Seydoux C, Goy JJ, et al. Repeated intracoronary beta radiation for recurrent in-stent restenosis. *Catheterizat Cardiovasc Interv*. 2002; 55:233-6.
47. DeCunha JM, Enger SA. A new delivery system to resolve dosimetric issues in intravascular brachytherapy. *Brachytherapy*. 2018 May 1;17(3): 634-43.